ddp4 and glp 1 The multiple actions of dipeptidyl peptidase 4 (DPP-4) its pharmacological inhibition on bone metabolism: a review | Diabetology & Metabolic Syndrome GLP-1 Agonists and DPP-4 Inhibitors

The immunological findings defined CFS as a low-grade inflammatory disease, indicated by enhanced production of cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and nuclear factor kappa B (NF-B), dysregulated cytokine levels (increased levels of IL-1, IL-4, IL-5, IL-6, and IL-12 and decreased levels of IL-8, IL-13, and IL-15), autoimmune reactions, oxidative and nitrosative stress, reduced levels of antioxidant markers, mitochondrial dysfunction, increased translocation of Gram-negative bacteria, and altered antiviral response elements (i.e

Youdim says

While traditionally recognized for its role in glucose homeostasis and insulin secretion, GLP-1 exerts significant effects on the central nervous system through activation of GLP-1 receptors (GLP-1R) distributed throughout various brain regions

The enzyme dechlorinates DCA to glyoxylate inactivating it (Fig

This is basically asking your insurance company for permission to cover the medication, especially if it's not automatically on their list of approved drugs